Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human chorionic gonadotrophin
- Development stage
- Approved
- Lead developer
- Organon
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
Human chorionic gonadotrophin (hCG) is a polypeptide hormone produced by the human placenta. As a pharmaceutical product, it is purified from the urine of pregnant women or produced via recombinant technology. hCG mimics the action of luteinizing hormone (LH) by binding to and activating the LH/chorionic gonadotropin receptor in target tissues. In females, it stimulates ovulation and supports corpus luteum function to promote progesterone production; in males, it stimulates Leydig cells in the testes to produce testosterone and can be used for hypogonadotropic hypogonadism or prepubertal cryptorchidism. It is primarily indicated for infertility treatment in women (to induce ovulation), male infertility due to low sperm count or delayed puberty due to pituitary dysfunction, and undescended testes in boys not caused by anatomical obstruction[1][2][3][4][5][7]. hCG should not be used for weight loss as there is no evidence supporting efficacy for this indication[1][6].
- Brand names
- PregnylNovarelOvidrelProfasiChorexA.P.L.
- Other names
- chorionic gonadotropin (human)choriogonadotropin alfa
02
Targets
TSHR (Thyroid-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on human chorionic gonadotrophin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human chorionic gonadotrophin.